Labcorp outlines strategic priorities and long-term financial outlook at its 2026 Investor Day
The company reaffirms 2026 guidance and projects compound annual revenue growth of 5% to 8% through 2029.
See the latest news and media coverage for Labcorp. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical laboratory and drug development services provider
labcorp.comLast updated
In short: Labcorp delivered strong financial growth, launched an FDA-cleared Alzheimer's blood test, and expanded its global laboratory footprint.
The company reaffirms 2026 guidance and projects compound annual revenue growth of 5% to 8% through 2029.
The deal establishes Labcorp as the only central lab provider with wholly owned networks across four continents, strengthening biomarker and clinical trial services. This move enhances operational scale and regulatory oversight for multinational trials.
The companion diagnostic identifies advanced melanoma patients eligible for FDA-approved targeted therapies, supporting personalized treatment and expanding Labcorp's precision medicine portfolio.
Revenue increased 5.8% to $3.73 billion, adjusted EPS up 14.9% to $4.99.
"For individuals and families seeking answers about cognitive changes, the path to evaluation can be...
On October 03, 2023, Barclays maintained its Equal-Weight rating on Labcorp Holdings (LH), with an...
At the close on September 10, 2026, Labcorp stock extended losses after its Investor Day, with shares sliding about 4.3% and finishing near USD 307...
Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial...
Track Labcorp and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Labcorp and other trending companies.